Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting - Scorecard - MDSpire

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting

  • By

  • Yong Lin Wang

  • Chao Zhu

  • Mahima Kapoor

  • Gary Cutter

  • Carolina Barnett-Tapia

  • Helmut Butzkueven

  • Wenwen Zhang

  • Gabor Lovas

  • Csilla Rozsa

  • Jeannine Heckmann

  • Stefan Blum

  • Laurie McLaughlin

  • Katherine Buzzard

  • Yi Chao Foong

  • Elisabeth Chroni

  • Dimitra Veltsista

  • Belinda Cruse

  • Mina Botrous

  • Stephen Reddel

  • Mastura Monif

  • Anneke van der Walt

  • July 2, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating Rituximab's Effectiveness in Myasthenia Gravis: A Real-World Analysis Utilizing Inverse Probability of Treatment Weighting

At a Glance

CategoryDetail
ConditionMyasthenia Gravis
Key MechanismsAntibody-mediated dysfunction at the neuromuscular junction.
Target PopulationAChR-Ab positive Myasthenia Gravis patients.
Care SettingReal-world observational registry study.

Key Highlights

  • Rituximab did not show improved time-to-improvement compared to second NSIST.
  • 169 patients were included in the time-to-event analysis.
  • No statistical difference in hazard ratio between treatments (HR = 1.27, p = 0.48).
  • Study utilized inverse probability of treatment weighting for confounding adjustment.
  • Primary outcome was a composite clinical endpoint representing patient acceptable symptom state.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of Myasthenia Gravis confirmed by AChR-Ab positive serology.

Management

  • Initial treatment typically involves corticosteroids, with additional NSISTs for steroid-sparing.

Monitoring & Follow-up

  • Regular assessments of Myasthenia Gravis Composite (MGC) score.

Risks

  • Corticosteroids have significant adverse effects impacting quality of life.

Patient & Prescribing Data

Patients with AChR-Ab positive Myasthenia Gravis.

Rituximab is often used in refractory cases but lacks definitive comparative effectiveness evidence.

Clinical Best Practices

  • Consider corticosteroids as first-line treatment for Myasthenia Gravis.
  • Evaluate the need for additional NSISTs based on patient response to corticosteroids.
  • Utilize IPTW methods to adjust for confounding in observational studies.

Related Resources & Content

Original Source(s)

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting

  • by Yong Lin Wang, Chao Zhu, Mahima Kapoor, Gary Cutter, Carolina Barnett-Tapia, Helmut Butzkueven, Wenwen Zhang, Gabor Lovas, Csilla Rozsa, Jeannine Heckmann, Stefan Blum, Laurie McLaughlin, Katherine Buzzard, Yi Chao Foong, Elisabeth Chroni, Dimitra Veltsista, Belinda Cruse, Mina Botrous, Stephen Reddel, Mastura Monif, Anneke van der Walt

  • July 2, 2026

Related Content

New Alzheimer’s blood test may tell when symptoms are around the corner

  • July 1, 2026

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

  • July 1, 2026

  • 1 min
Blood-activating, depression-relieving formula alleviates post-stroke depression: mechanistic insights from network pharmacology and microglial validation